HC Wainwright restated their hold rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Wednesday, AnalystRatings.com reports. HC Wainwright currently has a $10.00 price target on the stock.
Other analysts also recently issued reports about the stock. ValuEngine upgraded shares of Syros Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, October 17th. Cowen restated a buy rating on shares of Syros Pharmaceuticals in a research report on Tuesday, November 12th. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a hold rating to a buy rating and set a $7.25 price target on the stock in a research report on Wednesday, October 23rd. Piper Jaffray Companies dropped their price target on shares of Syros Pharmaceuticals from $24.00 to $18.00 in a research report on Thursday, October 17th. Finally, BidaskClub upgraded shares of Syros Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, October 18th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Syros Pharmaceuticals currently has a consensus rating of Buy and a consensus price target of $13.46.
SYRS stock traded down $0.21 during mid-day trading on Wednesday, hitting $4.99. 475,500 shares of the company were exchanged, compared to its average volume of 370,191. Syros Pharmaceuticals has a twelve month low of $4.88 and a twelve month high of $11.93. The company has a market capitalization of $220.69 million, a PE ratio of -2.61 and a beta of 1.49. The firm has a fifty day simple moving average of $7.08 and a 200 day simple moving average of $7.94. The company has a current ratio of 4.92, a quick ratio of 8.11 and a debt-to-equity ratio of 0.20.
In other Syros Pharmaceuticals news, insider Jeremy P. Springhorn acquired 9,879 shares of the stock in a transaction dated Monday, November 11th. The shares were bought at an average price of $4.99 per share, with a total value of $49,296.21. Following the purchase, the insider now directly owns 24,879 shares of the company’s stock, valued at approximately $124,146.21. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 14.80% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in SYRS. Bank of Montreal Can grew its stake in shares of Syros Pharmaceuticals by 11,319.2% in the 2nd quarter. Bank of Montreal Can now owns 2,969 shares of the company’s stock worth $27,000 after purchasing an additional 2,943 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Syros Pharmaceuticals by 863.4% in the third quarter. Tower Research Capital LLC TRC now owns 2,688 shares of the company’s stock worth $28,000 after acquiring an additional 2,409 shares in the last quarter. A.R.T. Advisors LLC purchased a new position in shares of Syros Pharmaceuticals in the second quarter worth approximately $119,000. Susquehanna International Group LLP purchased a new position in shares of Syros Pharmaceuticals in the second quarter worth approximately $133,000. Finally, Algert Global LLC purchased a new position in shares of Syros Pharmaceuticals in the second quarter worth approximately $166,000. 93.14% of the stock is currently owned by institutional investors.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Featured Story: Swap
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.